TakedaTSE4502NYSETAK today announced positive topline results from a Phase 2 randomized doubleblind placebocontrolled study evaluating the safety tolerability and efficacy of mezagitamab TAK079 in patients with persistent or chronic primary immune thrombocytopenia ITP.